Coley Coleman
When someone survives a heart attack, the battle isn’t always over. In fact, nearly one-third of survivors go on to develop heart failure—a progressive weakening of the heart muscle that affects millions and contributes to roughly 500,000 deaths in the U.S. each year.
Dr. Noor Momin, the Stephenson Foundation Term Assistant Professor of Innovation in Bioengineering at Penn, is working to change that. Her lab’s innovative approach to immune modulation after heart attacks has just been recognized with the prestigious American Heart Association (AHA) Transformational Project Award for 2025. This award supports groundbreaking ideas that hold the potential to significantlya dvance cardiovascular and cerebrovascular research.
A Targeted Strategy to Prevent Heart Failure
Following a heart attack, the immune system springs into action to repair damaged tissue. But when that response lingers or becomes excessive, it can cause additional harm—like a repair crew overstaying its welcome and inadvertently worsening the damage.
Momin’s lab is developing a targeted strategy using cytokines to control this immune response. Cytokines are used by immune cells to communicate with each other and other cells. Instead of delivering just a cytokine, which can lead to harmful side effects in healthy tissues, they’ve re-engineered it to home to damaged heart tissue. Early preclinical tests have shown that this approach can prevent heart failure with minimal side effects.